貴州百靈(002424.SZ)擬投建前提取三車間及配套工程項目
格隆匯3月2日丨貴州百靈(002424.SZ)公佈,公司擬投資建設“前提取三車間及配套工程項目”,項目總投資5.98億元,公司將以自有資金2億元進行首期投資,後續投資款項公司將根據項目工程進度及資金需求情況通過多種融資方式進行融資。
該項目主要生產線包括:前處理車間、甲類提取車間、丙類提取車間等。項目建成後預計年可處理23000餘噸幹藥材,可提供公司31個品種藥品的生產所需,涉及主要產品包括銀丹心腦通軟膠囊、小兒柴桂退熱顆粒、雙羊喉痺通顆粒、咳速停糖漿及膠囊、金感膠囊等產品。
公司新建前提取三車間及配套工程項目,將以充分滿足自身生產需要為首要條件,通過從源頭控制產品質量,進一步完善公司產業鏈,夯實公司在我國中成藥領域的競爭力。該項目建成投產後,將確保公司高起點、高標準、高效率的提取工藝技術,能進一步提高核心競爭力,實現產品質量、主營業務收入與利潤水平的提高,強化公司在苗藥領域的龍頭地位,提升公司在中藥領域的核心競爭優勢,符合公司整體戰略規劃和長遠發展需要,符合公司和全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.